Business
Non Regulatory Appnt of Senior Scientific Advisor
Non Regulatory Appnt of Senior Scientific Advisor.
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n\nRNS Reach - non-regulatory announcement\n \n30 July 2024\n \nGraft Polymer (UK) plc (LON: GPL)\nAppointment of Senior Scientific Adviser\nProfessor David Nutt - renowned leader in neuroscience and public health\n \nGraft Polymer (UK) plc (\"Graft Polymer\" or the \"Company\"), an innovative drug delivery systems development company, is pleased to announce the appointment of Professor David Nutt as the Company's Senior Scientific Adviser, effective immediately.\n \nThis appointment follows the announcement, on 18 July 2024, of Graft Polymer's collaboration agreement with Awakn Life Sciences Corp (CSE:AWKN OTCQB:AWKNF) (\"Awakn\").\n \nProfessor Nutt, a preeminent authority in neuropsychopharmacology, is a Professor at Imperial College London and Chief Research Officer at Awakn. He is renowned for his leadership role in development of UK drug policy research, having chaired the UK Advisory Council on the Misuse of Drugs, and led numerous influential studies on the effects of drugs on the brain and public health. Professor Nutt has made significant contributions to the UK's understanding and treatment of mental health disorders and addiction. His work has been instrumental in shaping evidence-based policies and treatment protocols, earning him recognition as one of the most influential voices in UK neuroscience and public health.\n \nIn consideration for becoming the Company's Senior Scientific Adviser Professor Nutt has been granted 10,000,000 nominal cost options (with an exercise price of £0.001) over the Company's ordinary shares under the Company's Long Term Incentive Plan (the \"LTIP\"). These options will have a term of three years from the date of grant and will vest in three equal parts: one third immediately, one third on the first anniversary, and the final third on the second anniversary of Professor Nutt's appointment. Following this grant, the Company has a total of 10,000,000 outstanding options, equivalent to 0.4% of the Company's current issued share capital.\n \nCommenting on the appointment, Anthony Tennyson, CEO of Graft Polymer, said:\n\"We are honoured to welcome Professor Nutt as our Senior Scientific Adviser. His unparalleled expertise and leadership in UK research will be a tremendous asset to our team and his work aligns perfectly with our mission to innov...